AR085666A1 - Derivados de c4-monometil triterpenoides y una composicion farmaceutica - Google Patents
Derivados de c4-monometil triterpenoides y una composicion farmaceuticaInfo
- Publication number
- AR085666A1 AR085666A1 ARP120100803A ARP120100803A AR085666A1 AR 085666 A1 AR085666 A1 AR 085666A1 AR P120100803 A ARP120100803 A AR P120100803A AR P120100803 A ARP120100803 A AR P120100803A AR 085666 A1 AR085666 A1 AR 085666A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- alkylamino
- alkoxy
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
Los compuestos de la presente son útiles en el tratamiento y prevención de enfermedades inflamatorias y proliferativas.Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) donde: X1 y X2 son en forma independiente hidrógeno, halo, hidroxi, amino o oxo, con la condición de que X1 no es oxo cuando los átomos de carbono 12 y 13 están conectados entre sí con una unión doble, además con la condición de que X2 no es oxo cuando los átomos de carbono 9 y 11 están conectados entre sí con una unión doble; R1 es -H, -CN, halo, -CF3, o -C(O)Ra, donde Ra es -OH, alcoxi C1-4, -NH2, alquilamino C1-4, o -NH-S(O)2-alquilo C1-4; R2 es hidrógeno o R2 se encuentra ausente cuando el átomo al cual está unido forma parte de una unión doble; R2’ es hidrógeno, =CH2, alquilo C£8, o alquilo C£8 sustituido; R3 y R4 son en forma independiente entre sí hidrógeno, hidroxi, metilo o como se define más adelante cuando cualquiera de estos grupos se toma junto con el grupo Rc; e Y es: -H, -OH, -SH, -CN, -F, -CF3, -NH2 o -NCO; alquilo C£8, alquenilo C£8, alquinilo C£8, arilo C£12, aralquilo C£12, heteroarilo C£8, heterocicloalquilo C£12, alcoxi C£8, ariloxi C£12, aciloxi C£8, alquilamino C£8, dialquilamino C£8, alquenilamino C£8, arilamino C£8, aralquilamino C£8, alquiltio C£8, aciltio C£8, alquilsulfonilamino C£8, o versiones sustituidas de cualquiera de estos grupos; -alcanodiil C£8-Rb, -alquenodiil C£8-Rb, o una versión sustituida de cualquiera de estos grupos, donde Rb es: hidrógeno, hidroxi, halo, amino o tio; o heteroarilo C£8, alcoxi C£8, alqueniloxi C£8, ariloxi C£8, aralcoxi C£8, heteroariloxi C£8, aciloxi C£8, alquilamino C£8, dialquilamino C£8,alquenilamino C£8, arilamino C£8, aralquilamino C£8, heteroarilamino C£8, alquilsulfonilamino C£8, amido C£8, -OC(O)NH-alquilo C£8,-OC(O)CH2NHC(O)O-t-butilo, -OCH2-alquiltio C£8, o una versión sustituida de cualquiera de estos grupos; -(CH2)mC(O)Rc, donde m es 0 - 6 y Rc es: hidrógeno, hidroxi, halo, amino, -NHOH, un resto de fórmula (2) o tio; o alquilo C£8, alquenilo C£8, alquinilo C£8, arilo C£8, aralquilo C£8, heteroarilo C£8, heterocicloalquilo C£8, alcoxi C£8, alqueniloxi C£8, ariloxi C£8, aralcoxi C£8, heteroariloxi C£8, aciloxi C£8, alquilamino C£8, dialquilamino C£8, arilamino C£8, alquilsulfonilamino C£8, amido C£8, -NH-alcoxi C£8, -NH-heterocicloalquilo C£8, -NHC(NOH)-alquilo C£8, -NH-amido C£8, o una versión sustituida de cualquiera de estos grupos; Rc y R3, tomados juntos, son -O- o -NRd-, donde Rd es hidrógeno o alquilo C£4; o Rc y R4, tomados juntos, son -O- o -NRd-, donde Rd es hidrógeno o alquilo C£4; o -NHC(O)Re, donde Re es: hidrógeno, hidroxi, amino; o alquilo C£8, alquenilo C£8, alquinilo C£8, arilo C£8, aralquilo C£8, heteroarilo C£8,heterocicloalquilo C£8, alcoxi C£8, ariloxi C£8, aralcoxi C£8, heteroariloxi C£8, aciloxi C£8, alquilamino C£8, dialquilamino C£8, arilamino C£8, o una versión sustituida de cualquiera de estos grupos; o una sal farmacéuticamente aceptable o tautómero del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452017P | 2011-03-11 | 2011-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085666A1 true AR085666A1 (es) | 2013-10-16 |
Family
ID=45856041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100803A AR085666A1 (es) | 2011-03-11 | 2012-03-12 | Derivados de c4-monometil triterpenoides y una composicion farmaceutica |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9290536B2 (es) |
| EP (1) | EP2683731B1 (es) |
| JP (1) | JP6129084B2 (es) |
| KR (1) | KR101956399B1 (es) |
| CN (1) | CN103619866B (es) |
| AR (1) | AR085666A1 (es) |
| AU (1) | AU2012229244B2 (es) |
| BR (1) | BR112013023174B1 (es) |
| CA (1) | CA2829618C (es) |
| CL (1) | CL2013002612A1 (es) |
| CO (1) | CO6801741A2 (es) |
| CY (1) | CY1121744T1 (es) |
| DK (1) | DK2683731T3 (es) |
| EA (1) | EA026847B1 (es) |
| ES (1) | ES2729405T3 (es) |
| HR (1) | HRP20191164T1 (es) |
| HU (1) | HUE044081T2 (es) |
| IL (1) | IL228297B (es) |
| LT (1) | LT2683731T (es) |
| ME (1) | ME03469B (es) |
| MX (1) | MX348862B (es) |
| PL (1) | PL2683731T3 (es) |
| PT (1) | PT2683731T (es) |
| RS (1) | RS59200B1 (es) |
| SG (1) | SG193404A1 (es) |
| SI (1) | SI2683731T1 (es) |
| SM (1) | SMT201900433T1 (es) |
| TR (1) | TR201909788T4 (es) |
| TW (1) | TWI535731B (es) |
| UY (1) | UY33946A (es) |
| WO (1) | WO2012125488A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| RS58486B1 (sr) | 2008-01-11 | 2019-04-30 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
| NZ588710A (en) | 2008-04-18 | 2012-12-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
| US7943778B2 (en) | 2008-04-18 | 2011-05-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
| EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ | 単環式シアノエノンおよびその使用方法説明 |
| SMT201800069T1 (it) | 2010-12-17 | 2018-03-08 | Reata Pharmaceuticals Inc | Pirazolil- e pirimidinilenoni triciclici quali modulatori d'infiammazione antiossidanti |
| SG193404A1 (en) | 2011-03-11 | 2013-10-30 | Reata Pharmaceuticals Inc | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| PL2841445T3 (pl) | 2012-04-27 | 2017-10-31 | Reata Pharmaceuticals Inc | Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, formy polimorficzne oraz sposoby ich stosowania |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| SI2892911T1 (sl) * | 2012-09-10 | 2017-12-29 | Reata Pharmaceuticals, Inc. | C17-heteroarilni derivati oleanolne kisline in postopki njihove uporabe |
| HUE044126T2 (hu) * | 2012-09-10 | 2019-09-30 | Reata Pharmaceuticals Inc | Oleanolsav C17-alkándiil- és alkéndiil-származékai, és eljárás azok elõállítására |
| WO2014040073A1 (en) * | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US20140073700A1 (en) * | 2012-09-10 | 2014-03-13 | Abbvie Inc. | Glycyrrhetinic acid derivatives and methods of use thereof |
| TW201514192A (zh) | 2013-03-19 | 2015-04-16 | Daiichi Sankyo Co Ltd | 萜類衍生物 |
| TW201936625A (zh) | 2013-04-24 | 2019-09-16 | 美商艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| CA2814303A1 (en) | 2013-04-26 | 2014-10-26 | Cellphone-Mate, Inc. | Apparatus and methods for radio frequency signal boosters |
| CN104861028A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型熊果酸衍生物、其制备方法及其应用 |
| CN104861027A (zh) * | 2014-02-24 | 2015-08-26 | 上海兰蒂斯生物医药科技有限公司 | 新型齐墩果酸衍生物、其制备方法及其应用 |
| KR20170055482A (ko) | 2014-09-10 | 2017-05-19 | 다이이찌 산쿄 가부시키가이샤 | 안질환 치료용 및 예방용 서방성 의약 조성물 |
| AU2016219109B2 (en) | 2015-02-12 | 2020-05-14 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| CN108290922B (zh) * | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
| CN105820207A (zh) * | 2016-03-24 | 2016-08-03 | 庄立 | 一种茴拉西坦的药物组合物及其抗氧化作用 |
| JP6633812B2 (ja) | 2016-11-08 | 2020-01-22 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| CN112654610B (zh) | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| MX2021003643A (es) * | 2018-09-28 | 2021-08-19 | Sichuan Haisco Pharmaceutical Co Ltd | Derivados de terpenoides y usos de los mismos. |
| US20210040142A1 (en) * | 2019-07-19 | 2021-02-11 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| WO2022126129A1 (en) | 2020-12-11 | 2022-06-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids for use in therapy |
| JP2024504637A (ja) | 2021-01-18 | 2024-02-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 合成ウルソール酸誘導体及びその使用方法 |
| MX2024008443A (es) | 2022-02-16 | 2024-07-19 | Firmenich & Cie | Proceso de preparacion de derivados de octahidro-2(1h)-naftalenona . |
| GB202211190D0 (en) * | 2022-08-01 | 2022-09-14 | Royal College Surgeons Ireland | Fluorination process |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| ES2295031T3 (es) | 1999-05-14 | 2008-04-16 | Nereus Pharmaceuticals, Inc. | Nuevos moduladores de interleucina-1 y factor de necrosis tumoral, sintesis de dichos moduladores y metodos de uso de dichos moduladores. |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| WO2002026762A1 (en) | 2000-09-29 | 2002-04-04 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
| AU2001294953A1 (en) | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| US20040234977A1 (en) | 2001-05-14 | 2004-11-25 | Da-Wei Gong | Novel alanine transaminase enzyme and methods of use |
| EP1465615B1 (en) | 2002-01-15 | 2012-08-01 | Trustees of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| ATE417857T1 (de) | 2002-01-18 | 2009-01-15 | Univ Minnesota | Quaternäre terpensalze als biologisch aktive tenside |
| US6974801B2 (en) | 2002-05-13 | 2005-12-13 | The Trustees Of Dartmounth College | Inhibitors and methods of use thereof |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| EP1811840B1 (en) | 2004-09-07 | 2016-04-13 | May Sung Mak | Anti-tumor compounds with angeloyl groups |
| EP1959969A2 (en) | 2005-07-01 | 2008-08-27 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
| CN101117348B (zh) | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| CA2670099A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| JP2008247898A (ja) | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| RS58486B1 (sr) | 2008-01-11 | 2019-04-30 | Reata Pharmaceuticals Inc | Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti |
| EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
| US7943778B2 (en) | 2008-04-18 | 2011-05-17 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives |
| NZ588710A (en) | 2008-04-18 | 2012-12-21 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
| JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ | 単環式シアノエノンおよびその使用方法説明 |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| US8747901B2 (en) | 2009-02-13 | 2014-06-10 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
| CN101704874A (zh) * | 2009-11-26 | 2010-05-12 | 中国药科大学 | 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途 |
| SG10201808661XA (en) | 2010-04-12 | 2018-11-29 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
| WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
| SG192144A1 (en) | 2011-01-31 | 2013-08-30 | Bristol Myers Squibb Co | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| SG193404A1 (en) | 2011-03-11 | 2013-10-30 | Reata Pharmaceuticals Inc | C4-monomethyl triterpenoid derivatives and methods of use thereof |
-
2012
- 2012-03-09 SG SG2013068291A patent/SG193404A1/en unknown
- 2012-03-09 ES ES12709768T patent/ES2729405T3/es active Active
- 2012-03-09 CN CN201280022645.4A patent/CN103619866B/zh active Active
- 2012-03-09 PL PL12709768T patent/PL2683731T3/pl unknown
- 2012-03-09 KR KR1020137026782A patent/KR101956399B1/ko active IP Right Grant
- 2012-03-09 EA EA201391313A patent/EA026847B1/ru unknown
- 2012-03-09 PT PT12709768T patent/PT2683731T/pt unknown
- 2012-03-09 CA CA2829618A patent/CA2829618C/en active Active
- 2012-03-09 WO PCT/US2012/028569 patent/WO2012125488A1/en active Application Filing
- 2012-03-09 JP JP2013557919A patent/JP6129084B2/ja active Active
- 2012-03-09 SI SI201231611T patent/SI2683731T1/sl unknown
- 2012-03-09 TR TR2019/09788T patent/TR201909788T4/tr unknown
- 2012-03-09 HU HUE12709768A patent/HUE044081T2/hu unknown
- 2012-03-09 EP EP12709768.1A patent/EP2683731B1/en active Active
- 2012-03-09 AU AU2012229244A patent/AU2012229244B2/en active Active
- 2012-03-09 SM SM20190433T patent/SMT201900433T1/it unknown
- 2012-03-09 UY UY0001033946A patent/UY33946A/es not_active Application Discontinuation
- 2012-03-09 RS RSP20190859 patent/RS59200B1/sr unknown
- 2012-03-09 BR BR112013023174-2A patent/BR112013023174B1/pt active IP Right Grant
- 2012-03-09 DK DK12709768.1T patent/DK2683731T3/da active
- 2012-03-09 MX MX2013010429A patent/MX348862B/es active IP Right Grant
- 2012-03-09 LT LTEP12709768.1T patent/LT2683731T/lt unknown
- 2012-03-09 ME MEP-2019-168A patent/ME03469B/me unknown
- 2012-03-12 US US13/417,519 patent/US9290536B2/en active Active
- 2012-03-12 AR ARP120100803A patent/AR085666A1/es unknown
- 2012-03-12 TW TW101108395A patent/TWI535731B/zh active
-
2013
- 2013-09-08 IL IL228297A patent/IL228297B/en active IP Right Grant
- 2013-09-11 CL CL2013002612A patent/CL2013002612A1/es unknown
- 2013-10-09 CO CO13240105A patent/CO6801741A2/es not_active Application Discontinuation
-
2019
- 2019-06-27 HR HRP20191164TT patent/HRP20191164T1/hr unknown
- 2019-07-01 CY CY20191100690T patent/CY1121744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085666A1 (es) | Derivados de c4-monometil triterpenoides y una composicion farmaceutica | |
| AR084353A1 (es) | Enonas triciclicas de pirazolilo y pirimidinilo utiles como agentes antiinflamatorios y/o antioxidantes y composiciones farmaceuticas que las contienen | |
| CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
| AR078507A1 (es) | Compuestos lipidicos, composiciones farmaceuticas, usos y metodo de preparacion | |
| RS54207B1 (en) | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | |
| ES2722048T3 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CL2011002990A1 (es) | Compuestos derivados de bifenilo, inhibidores de endopeptidasa neutra (nep); composición farmacéutica; combinación farmacéutica; uso del compuesto para tratar un trastorno o enfermedad tal como la hipertensión, insuficiencia cardiaca, insuficiencia renal, glaucoma, trastornos reproductivos, entre otros. | |
| AR079055A1 (es) | Procedimiento para la preparacion de dabigatran etexilato e intermediarios del mismo | |
| SI2820009T1 (en) | Serine / Threonine kinase inhibitors | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CY1118771T1 (el) | Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων | |
| PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| AR086522A1 (es) | Inhibidores heterociclicos de autotaxina y usos de los mismos | |
| RS53469B (en) | UNITS THAT MODULATE ANDROGEN RECEPTOR | |
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| TN2016000210A1 (en) | Urea derivative or pharmacologically acceptable salt thereof. | |
| EA201291246A1 (ru) | Конденсированные бициклические ингибиторы киназы | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| AR080802A1 (es) | Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| NZ740723A (en) | Piperidinobenzodiazepine compounds with anti proliferative activity | |
| AR079957A1 (es) | Derivados de acidos grasos de salicilatos composiciones farmaceuticas y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |